<DOC>
	<DOCNO>NCT00369733</DOCNO>
	<brief_summary>To assess effect Aranesp hemoglobin ( Hgb ) CRI subject recombinant human erythropoietin ( rHuEPO ) -naïve convert rHuEPO therapy .</brief_summary>
	<brief_title>STAAR-3 Clinical Study</brief_title>
	<detailed_description>To assess effect Aranesp hemoglobin CRI subjectswho recombinant human erythropoetin ( rHuEPO ) -naïve convert rHuEPO therapy ass association subject self-reported health-related quality life ( HRQoL ) relate Hgb concentration glomerular filtration rate ( GFR ) subject rHuEPO-naïve prior study enrollment . To characterize health-related resource utilization subject CRI . To characterize subject satisfaction Aranesp™ compare previous rHuEPO therapy . To characterize iron treatment subject CRI . To evaluate extent implementation case management contributes achieve desired clinical objective . To assess safety profile Aranesp™ therapy subject CRI .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>diagnosis CRI receive dialysis therapy ( must predialysis ) measure estimate ( use CockcroftGault formula ) creatinine clearance ( CrCl ) ≤ 70 mL/min , GFR ≤ 60 mL/min ( use MDRD formula ) : CockcroftGault formula : CrCl = ( 140 minus age year ) x ( body weight kg ) serum creatinine ( mg/dL ) x 72.0 . For woman , value multiply 0.85 MDRD formula : GFR = 170 x [ SCr ] 0.999 x [ Age ] 0.167 x [ 0.762 subject female ] x [ 1.180 subject black ] x [ SUN ] 0.170 x [ SAlb ] 0.318 ( subject already receive rHuEPO therapy ) mean Hgb &lt; 11 g/dL screening/baseline period subject currently receive rHuEPO therapy , subject must : stable rHuEPO dose past month ; rHuEPO frequency weekly . white blood cell platelet count within normal limit serum vitamin B12 folate level low limit normal range transferrin saturation ( TSAT ) ≥ 20 % screening period availability followup assessment subject must able comprehend willing , legally accept representative , give write informed consent participation study schedule initiate dialysis uncontrolled hypertension ( diastolic blood pressure &gt; 105 mm Hg systolic blood pressure &gt; 180 mm Hg screening/baseline period two separate measurement ) clinically unstable judgment investigator ( eg , subject intensive care unit , immediately postmyocardial infarction , etc ) schedule receive living donor kidney transplant treatment grand mal epilepsy within past 6 month moderate severe congestive heart failure ( NYHA class III IV ) clinical evidence severe secondary hyperparathyroidism ( parathyroid hormone level &gt; 1500 pg/mL ) severe active chronic inflammatory process ( eg , ulcerative colitis , peptic ulcer disease , rheumatoid arthritis , etc ) currently receive antibiotic therapy systemic infection ( enrollment may postpone course antibiotic end ) know aspartate aminotransferase ( AST ) alanine aminitransferase ( ALT ) great 3 time upper limit normal range one occasion within three month prior screen know positive HIV antibody hepatitis B surface antigen clinical evidence current malignancy and/or receive chemotherapy exception basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia active bleeding RBC transfusion within eight week enrollment androgen therapy within four week enrollment know hematologic disease ( eg , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma ; hemolytic anemia , etc ) condition likely affect subject compliance currently previously ( within 30 day ) enrol investigational device drug trial ( ) receive investigational agent ( ) exception subject enrol another Aranesp™ rHuEPO protocol pregnant breast feed woman ( woman childbearing potential must use contraceptive precaution ) woman plan child study period know hypersensitivity active substance excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Aranesp</keyword>
	<keyword>Anemia</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>QoL</keyword>
</DOC>